PMID- 35975917 OWN - NLM STAT- MEDLINE DCOM- 20220825 LR - 20230329 IS - 1532-2491 (Electronic) IS - 1082-6084 (Print) IS - 1082-6084 (Linking) VI - 57 IP - 11 DP - 2022 TI - Patient Characteristics Associated with Opioid Abstinence after Participation in a Trial of Buprenorphine versus Injectable Naltrexone. PG - 1732-1742 LID - 10.1080/10826084.2022.2112230 [doi] AB - Background and Objectives: Better understanding of predictors of opioid abstinence among patients with opioid use disorder (OUD) may help to inform interventions and personalize treatment plans. This analysis examined patient characteristics associated with opioid abstinence in the X:BOT (Extended-Release Naltrexone versus Buprenorphine for Opioid Treatment) trial. Methods: This post-hoc analysis examined factors associated with past-month opioid abstinence at the 36-week follow-up visit among participants in the X:BOT study. 428 participants (75% of original sample) attended the visit at 36 weeks. Logistic regression models were used to estimate the probability of opioid abstinence across various baseline sociodemographics, clinical characteristics, and treatment variables. Results: Of the 428 participants, 143 (33%) reported abstinence from non-prescribed opioids at the 36-week follow-up. Participants were more likely to be opioid abstinent if randomized to XR-NTX (compared to BUP-NX), were on XR-NTX at week 36 (compared to those off OUD pharmacotherapy), successfully inducted onto either study medication, had longer time on study medication, reported a greater number of abstinent weeks, or had longer time to relapse during the 24-week treatment trial. Participants were less likely to be abstinent if Hispanic, had a severe baseline Hamilton Depression Rating (HAM-D) score, or had baseline sedative use. Conclusions: A substantial proportion of participants was available at follow-up (75%), was on OUD pharmacotherapy (53%), and reported past-month opioid abstinence (33%) at 36 weeks. A minority of patients off medication for OUD reported abstinence and additional research is needed exploring patient characteristics that may be associated with successful treatment outcomes. FAU - Greiner, Miranda G AU - Greiner MG AUID- ORCID: 0000-0003-3768-527X AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Shulman, Matisyahu AU - Shulman M AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Scodes, Jennifer AU - Scodes J AUID- ORCID: 0000-0002-5006-7436 AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Choo, Tse-Hwei AU - Choo TH AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Pavlicova, Martina AU - Pavlicova M AD - Department of Biostatistics, Columbia University Mailman School of Public Health, New York, New York, USA. FAU - Opara, Onumara AU - Opara O AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Campbell, Aimee N C AU - Campbell ANC AUID- ORCID: 0000-0003-4247-9980 AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. FAU - Novo, Patricia AU - Novo P AD - Departments of Population Health and Psychiatry, New York University Grossman School of Medicine, New York, New York, USA. FAU - Fishman, Marc AU - Fishman M AD - Department of Psychiatry, Johns Hopkins University School of Medicine and Maryland Treatment Centers, Baltimore, Maryland, USA. FAU - Lee, Joshua D AU - Lee JD AUID- ORCID: 0000-0002-5907-0391 AD - Departments of Population Health and Psychiatry, New York University Grossman School of Medicine, New York, New York, USA. FAU - Rotrosen, John AU - Rotrosen J AUID- ORCID: 0000-0002-0283-5576 AD - Departments of Population Health and Psychiatry, New York University Grossman School of Medicine, New York, New York, USA. FAU - Nunes, Edward V AU - Nunes EV AUID- ORCID: 0000-0002-2055-3425 AD - Department of Psychiatry, New York State Psychiatric Institute and Columbia University Irving Medical Center, New York, New York, USA. LA - eng GR - T32 DA007294/DA/NIDA NIH HHS/United States GR - UG1 DA013035/DA/NIDA NIH HHS/United States PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, N.I.H., Extramural DEP - 20220817 PL - England TA - Subst Use Misuse JT - Substance use & misuse JID - 9602153 RN - 0 (Analgesics, Opioid) RN - 0 (Delayed-Action Preparations) RN - 0 (Narcotic Antagonists) RN - 40D3SCR4GZ (Buprenorphine) RN - 5S6W795CQM (Naltrexone) SB - IM MH - Analgesics, Opioid/therapeutic use MH - *Buprenorphine/therapeutic use MH - Delayed-Action Preparations/therapeutic use MH - Humans MH - Injections, Intramuscular MH - Naltrexone/therapeutic use MH - Narcotic Antagonists/therapeutic use MH - *Opioid-Related Disorders/drug therapy PMC - PMC10044490 MID - NIHMS1881217 OTO - NOTNLM OT - Opioid abstinence OT - buprenorphine OT - extended-release injectable naltrexone OT - opioid use disorder EDAT- 2022/08/18 06:00 MHDA- 2022/08/26 06:00 PMCR- 2023/03/28 CRDT- 2022/08/17 08:11 PHST- 2022/08/18 06:00 [pubmed] PHST- 2022/08/26 06:00 [medline] PHST- 2022/08/17 08:11 [entrez] PHST- 2023/03/28 00:00 [pmc-release] AID - 10.1080/10826084.2022.2112230 [doi] PST - ppublish SO - Subst Use Misuse. 2022;57(11):1732-1742. doi: 10.1080/10826084.2022.2112230. Epub 2022 Aug 17.